Authors' reply to Wardlaw and Berge

BMJ. 2015 Apr 7:350:h1795. doi: 10.1136/bmj.h1795.

Authors

Brian S Alper¹, Meghan Malone-Moses², James S McLellan², Kameshwar Prasad³, Eric Manheimer⁴

Affiliations

¹ DynaMed, EBSCO Health, EBSCO Information Services, Ipswich, MA 01938, USA balper@EBSCO.com.
² DynaMed, EBSCO Health, EBSCO Information Services, Ipswich, MA 01938, USA.
³ Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
⁴ Bahrain Branch of the Cochrane Collaboration, Awali, Bahrain.

PMID: 25851154
DOI: 10.1136/bmj.h1795

No abstract available

Publication types

Letter
Comment

MeSH terms

Evidence-Based Medicine*
Fibrinolytic Agents / therapeutic use*
Humans
Stroke / drug therapy*
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*

Substances

Fibrinolytic Agents
Tissue Plasminogen Activator